This article is the American Cancer Society’s update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010–2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989–2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016–2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black–White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

中文翻译：

---

2022 年乳腺癌统计数据

本文是美国癌症协会对美国女性乳腺癌统计数据的更新，包括基于人群的发病率、死亡率、存活率和乳房 X 光检查筛查数据。在过去四十年的大部分时间里，乳腺癌的发病率都在上升；在最近的数据年度（2010-2019 年），该比率每年增加 0.5%，这主要是受局限期和激素受体阳性疾病的推动。相比之下，乳腺癌死亡率自 1989 年达到顶峰以来一直稳步下降，尽管近年来的下降速度（2011 年至 2020 年每年下降 1.3%）低于过去十年（2002 年至 2011 年每年下降 1.9%）。总体而言，在 1989 年至 2020 年间，死亡率下降了 43%，这意味着在此期间乳腺癌死亡人数减少了 460,000 人。除美洲印第安人/阿拉斯加原住民外，所有种族/族裔群体的女性死亡率均出现类似下降，其中死亡率稳定。然而，尽管黑人女性与白人女性的发病率较低（每 100,000 人中分别有 127.8 人和 133.7 人），但乳腺癌死亡率的种族差异仍然坚定不移，黑人女性的总体死亡率高 40%（每 100,000 人中有 27.6 人和 19.7 人死亡） 2016-2020 年），50 岁以下成年女性的死亡率高出两倍（每 100,000 人中有 12.1 人死亡对 6.5 人死亡）。对于每个分子亚型和疾病阶段（I 期除外），黑人女性的 5 年相对存活率在所有种族/族裔群体中最低，在激素受体阳性/人类表皮生长因子的绝对值方面，黑人与白人之间的差距最大受体 2 阴性疾病（88% 对 96%），激素受体阴性/人表皮生长因子受体 2 阳性疾病（78% 对 86%）和 III 期疾病（64% 对 77%）。通过在全国范围内扩大医疗补助计划以及社区利益相关者、宣传组织和卫生系统之间的伙伴关系，增加获得高质量筛查和治疗的机会，从而减轻种族差异，可以加快降低乳腺癌死亡率的进展。